World Pharma News
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.
This page shows you the latest items in this publication.
225 records returned
FDA Advisory Committee Finds Data Support SPIRIVA® HandiHaler®
Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee voted 11 to 1 that clinical data included in a supplemental new drug application (sNDA) provide substantial and convincing evidence to support the claim that SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder) reduces exacerbations (worsening of symptoms) in patients with chronic obstructive pulmonary disease (COPD). (Source: World Pharma News)
Source: World Pharma News - November 20, 2009 Category: Pharmaceuticals Source Type: news
85% of Online Europeans Use the Internet for Health InformationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
In 2009, 85% of online Europeans in the United Kingdom, Germany, France, Italy, and Spain turn to the Internet and other technologies for health and prescription drug information, according to the latest Cybercitizen Health® Europe v9.0 study from healthcare and pharmaceutical market research company Manhattan Research. The collaboratively-edited Wikipedia again proves to be a top online health resource for consumers in all of the countries surveyed. (Source: World Pharma News)
Source: World Pharma News - November 20, 2009 Category: Pharmaceuticals Source Type: news
GSK and Nabi announce agreement for NicVAX®, a vaccine for nicotine addictionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
GlaxoSmithKline Biologicals SA (GSK) and Nabi Biopharmaceuticals (Nabi) announcedan exclusive worldwide option and licensing agreement for a nicotine conjugate candidate vaccine (NicVAX®), an investigational vaccine for the treatment of nicotine addiction and the prevention of smoking relapse, as well as for the development of a second generation nicotine vaccine. (Source: World Pharma News)
Source: World Pharma News - November 19, 2009 Category: Pharmaceuticals Source Type: news
AstraZeneca Submits US New Drug Application for Brilinta (Ticagrelor)Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
AstraZeneca today announced it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA. (Source: World Pharma News)
Source: World Pharma News - November 19, 2009 Category: Pharmaceuticals Source Type: news
Lower doses of antigen may suffice to generate a protective immune response against A(H1N1)Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Novartis announced new interim data from ongoing clinical trials demonstrating that a single 7.5µg dose of the company's influenza A(H1N1) 2009 unadjuvanted vaccine, half of the currently-approved US dose, fulfilled immune response criteria associated with protection in adults and the elderly (>=65 years of age). (Source: World Pharma News)
Source: World Pharma News - November 18, 2009 Category: Pharmaceuticals Source Type: news
Study Meets Primary Endpoint with 25 Percent LDL Reduction in Very High-Risk Patient PopulationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that data from the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were presented at the American Heart Association's Scientific Sessions. (Source: World Pharma News)
Source: World Pharma News - November 18, 2009 Category: Pharmaceuticals Source Type: news
BRILINTA Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical SettingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
AstraZeneca announced results of a PLATO sub-analysis in the most serious type of Acute Coronary Syndrome (ACS) patients, those with ST Segment Elevation Myocardial Infarction (STEMI). In this setting, ST segment elevation indicates total obstruction of a coronary artery which warrants emergency surgery with angioplasty, (Source: World Pharma News)
Source: World Pharma News - November 17, 2009 Category: Pharmaceuticals Source Type: news
Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent TechnologyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abbott (NYSE: ABT) today announced three-year data from the first 30 patients in the first phase of the ABSORB clinical trial, demonstrating that its fully bioabsorbable drug eluting coronary stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries. (Source: World Pharma News)
Source: World Pharma News - November 17, 2009 Category: Pharmaceuticals Source Type: news
Novartis launches Prevacid® 24 HR over-the-counterEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Novartis announced the availability of Prevacid®24HR (lansoprazole delayed-release capsules 15 mg/acid reducer) over-the-counter in pharmacies and retail stores across the US to treat frequent heartburn. Prevacid®24HR received US Food and Drug Administration (FDA) approval in May 2009. (Source: World Pharma News)
Source: World Pharma News - November 16, 2009 Category: Pharmaceuticals Source Type: news
Sanofi-aventis and Regeneron expand strategic Antibody CollaborationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies. (Source: World Pharma News)
Source: World Pharma News - November 16, 2009 Category: Pharmaceuticals Source Type: news
Abbott to Acquire Novel Investigational Biologic to Treat Chronic PainEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abbott (NYSE: ABT) announced a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain. (Source: World Pharma News)
Source: World Pharma News - November 13, 2009 Category: Pharmaceuticals Source Type: news
Nycomed reports continued satisfactory performance in the third quarter 2009Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
, with total net turnover increasing by 0.9% (3.2% in local currencies) to €820.0 million. Pantoprazole sales were resilient after losing patent protection in May in 12 European countries. On a regional basis, sales in most emerging markets exhibited strong growth. The pipeline portfolio advanced significantly. (Source: World Pharma News)
Source: World Pharma News - November 13, 2009 Category: Pharmaceuticals Source Type: news
FDA Commissioner Addresses Nation's Healthcare Professionals on H1N1 VaccineEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Dr. Margaret Hamburg, Commissioner of Food and Drugs, sent a letter to America's healthcare professionals thanking them for their efforts during the 2009 H1N1 influenza outbreak and providing information on the safety of the 2009 H1N1 vaccines. (Source: World Pharma News)
Source: World Pharma News - November 12, 2009 Category: Pharmaceuticals Source Type: news
FDA approves GSK's pandemic H1N1 vaccineEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
GlaxoSmithKline (GSK) announced that the US Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) for its unadjuvanted influenza A (H1N1) pandemic vaccine. (Source: World Pharma News)
Source: World Pharma News - November 12, 2009 Category: Pharmaceuticals Source Type: news
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global AgreementEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals, Inc., announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis. (Source: World Pharma News)
Source: World Pharma News - November 11, 2009 Category: Pharmaceuticals Source Type: news
International Diabetes Federation drives global action ahead of World Diabetes DayEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
In many countries, November is diabetes awareness month, with November 14 - World Diabetes Day - the most significant date on the diabetes calendar. The need to increase diabetes awareness grows ever year with the increasing impact of the disease worldwide. (Source: World Pharma News)
Source: World Pharma News - November 10, 2009 Category: Pharmaceuticals Source Type: news
European Partnership for Action against CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
At the end of September month, in Brussels, over 300 cancer organisations, patients and cancer survivors, health professionals, researchers, health authorities and health ministers gather to mark the official launch of the European Partnership for Action against Cancer. (Source: World Pharma News)
Source: World Pharma News - November 9, 2009 Category: Pharmaceuticals Source Type: news
WHO Grants Prequalification for Global Use to GSK's 10-Valent Synflorix™ VaccineEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The World Health Organization (WHO) has awarded prequalification for global use of Synflorix™, GlaxoSmithKline Biologicals' pneumococcal conjugate vaccine. This is the first prequalification for a vaccine against pneumococcal disease, which is a life-threatening disease affecting many children under five in developing countries. (Source: World Pharma News)
Source: World Pharma News - November 9, 2009 Category: Pharmaceuticals Source Type: news
Novartis to expand its human vaccines presence in ChinaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Novartis has reached an agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic initiative to build a vaccines industry leader in this country and expand the Group's limited presence in this fast-growing market segment. (Source: World Pharma News)
Source: World Pharma News - November 6, 2009 Category: Pharmaceuticals Source Type: news
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival. (Source: World Pharma News)
Source: World Pharma News - November 6, 2009 Category: Pharmaceuticals Source Type: news
New Merck Begins OperationsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Merck & Co., Inc. (NYSE: MRK) outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation. The new Merck is a global health care leader aimed at providing innovative, distinctive products and services that save and improve lives, while satisfying customer needs and creating long term shareholder value. (Source: World Pharma News)
Source: World Pharma News - November 5, 2009 Category: Pharmaceuticals Source Type: news
Abbott Completes Acquisition of Evalve, Inc.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abbott (NYSE: ABT) has completed its acquisition of Evalve, Inc., the global leader in the development of devices for minimally invasive repair of mitral valves. The acquisition provides Abbott with a leading presence in the growing area of non-surgical treatment for structural heart disease. (Source: World Pharma News)
Source: World Pharma News - November 4, 2009 Category: Pharmaceuticals Source Type: news
Pfizer and Medivation Initiate Two Phase 3 Trials of DimebonEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer's disease (AD). (Source: World Pharma News)
Source: World Pharma News - November 4, 2009 Category: Pharmaceuticals Source Type: news
Novartis announces USD 1 billion investment to build largest pharmaceutical R&D institute in ChinaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Novartis announced a USD 1 billion investment over the next five years, increasing R&D activities in China and confirming Novartis' long term commitment to China's further economic development, health reform and improving the health care of the Chinese people. The Novartis investment will include a significant expansion of The Novartis Institute of BioMedical Research (CNIBR) in Shanghai. (Source: World Pharma News)
Source: World Pharma News - November 4, 2009 Category: Pharmaceuticals Source Type: news
World's largest malaria vaccine trial now underway in seven African countriesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
A pivotal efficacy trial of RTS,S, the world's most clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. The trial, which is expected to involve up to 16,000 children, is on schedule, with more than 5,000 children already enrolled, researchers announced Tuesday at the 5th Multilateral Initiative on Malaria Pan-African Malaria Conference. (Source: World Pharma News)
Source: World Pharma News - November 4, 2009 Category: Pharmaceuticals Source Type: news
Sanofi-aventis delivers a solid performance in third quarter 2009Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
In the third quarter of 2009, sanofi-aventis generated net sales of €7,400 million, up 8.0% on a reported basis. Exchange rate movements had a favorable effect of 2.0 percentage points, with the appreciation of the U.S. dollar (and to a lesser extent the yen) against the euro more than offsetting the unfavorable effects of some other currencies. (Source: World Pharma News)
Source: World Pharma News - November 3, 2009 Category: Pharmaceuticals Source Type: news
Novartis on track to deliver Influenza A (H1N1) vaccine for the USEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Novartis has shipped over 7.5 million doses of Influenza A(H1N1)[1] vaccine ready to use and expects 25 to 30 million doses of unadjuvanted vaccine to become available in pre-filled syringes and multi-dose vials by the end of November. Smaller changes in delivery timelines and volumes can result out of the variability of the underlying biological production process. The deliveries are in line with commitments made to the US Department of Health and Human Services (HHS). (Source: World Pharma News)
Source: World Pharma News - November 2, 2009 Category: Pharmaceuticals Source Type: news
Lilly CEO Lechleiter Calls for Repair of the 'Engine of Biopharma Innovation'Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
In a speech to the City Club of San Diego, John C. Lechleiter, Ph.D., chairman and chief executive officer of Eli Lilly and Company (NYSE: LLY), said that the engine of biopharmaceutical innovation is "broken." He offered a vision for biopharmaceutical companies to "reinvent innovation" to make the most of today's wealth of scientific knowledge to benefit patients and address unmet medical needs. (Source: World Pharma News)
Source: World Pharma News - November 2, 2009 Category: Pharmaceuticals Source Type: news
Novel agent for treatment of Parkinson's disease - Lu 02-750Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase I clinical studies with Lu 02-750 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans. The placebo-controlled study is expected to enrol around 100 healthy individuals. (Source: World Pharma News)
Source: World Pharma News - October 31, 2009 Category: Pharmaceuticals Source Type: news
AstraZeneca PLC Third Quarter & Nine Months Results 2009Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Revenue in the third quarter increased by 10 percent at CER, but was up 5 percent on an actual basis as a result of the negative impact of exchange rate movements. Revenue benefited from strong growth of the Toprol-XL franchise in the US as a result of the market withdrawal by two generic competitors and from revenues from US government orders for vaccine for Novel Influenza A (H1N1); adjusting for these factors, global revenue increased by 5 percent. (Source: World Pharma News)
Source: World Pharma News - October 30, 2009 Category: Pharmaceuticals Source Type: news
Novo Nordisk increased operating profit by 30% in the first nine months of 2009Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Sales increased by 15% in Danish kroner and by 11% in local currencies:
Sales of modern insulins increased by 28% (24% in local currencies).
Sales of NovoSeven® increased by 15% (11% in local currencies).
Sales of Norditropin® increased by 15% (9% in local currencies).
Sales in North America increased by 29% (17% in local currencies).
Sales in International Operations increased by 18% (16% in local currencies). (Source: World Pharma News)
Source: World Pharma News - October 30, 2009 Category: Pharmaceuticals Source Type: news
Forest Laboratories, Inc. and Gedeon Richter Announce Results from a Phase IIb Study of CariprazineEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc announced positive top-line results from a Phase IIb clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of acute exacerbation of schizophrenia. (Source: World Pharma News)
Source: World Pharma News - October 29, 2009 Category: Pharmaceuticals Source Type: news
Abbott Completes Visiogen AcquisitionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abbott (NYSE: ABT) has completed its acquisition of privately held eye care company Visiogen, expanding the company's vision care business with a next-generation accommodating intraocular lens (IOL) technology to address presbyopia for cataract patients. (Source: World Pharma News)
Source: World Pharma News - October 29, 2009 Category: Pharmaceuticals Source Type: news
Boehringer Ingelheim Animal Health closes deal to acquire Animal Health Business from PfizerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Boehringer Ingelheim, a global pharmaceutical group of companies, together with its U.S. animal health business Boehringer Ingelheim Vetmedica, Inc., has closed its deal with Pfizer to acquire a significant portion of the Fort Dodge Animal Health business. (Source: World Pharma News)
Source: World Pharma News - October 28, 2009 Category: Pharmaceuticals Source Type: news
Pandemrix™ data in an elderly populationEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
GlaxoSmithKline (GSK) announced that this week, approximately half a million people will have received its pandemic H1N1 vaccine, Pandemrix™, as part of Government initiated vaccination programmes across Europe, which commenced earlier this month. GSK also announced new results from a clinical trial assessing the use of Pandemrix in adults aged 18 to 85 years of age. (Source: World Pharma News)
Source: World Pharma News - October 28, 2009 Category: Pharmaceuticals Source Type: news
Merck Revenues Increase by 2.7% to € 1.9 BillionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Merck KGaA announced that Group total revenues rose 2.7% in the third quarter to € 1,944 million from € 1,893 million in the year-ago quarter as the Pharmaceuticals divisions continued to grow and the Chemicals divisions continued to recover from the economic crisis. Royalty income declined 9.7% to € 82 million. (Source: World Pharma News)
Source: World Pharma News - October 27, 2009 Category: Pharmaceuticals Source Type: news
Novartis delivers strong new product momentum and operational performanceEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Novartis maintained the strong underlying momentum of 2009 as third-quarter net sales grew 7% in local currencies, while reported net sales rose 3% to USD 11.1 billion as four percentage points of growth were lost to adverse currency movements. (Source: World Pharma News)
Source: World Pharma News - October 27, 2009 Category: Pharmaceuticals Source Type: news
Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing AgreementEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Wellstat Therapeutics Corporation announced a global licensing agreement on PN2034, a novel oral first-in-class, insulin sensitizer, for the treatment of Type II Diabetes. As a sensitizer, PN2034 is expected to normalize and therefore enhance insulin action in the liver of diabetic patients. The compound is currently in Phase II clinical testing. (Source: World Pharma News)
Source: World Pharma News - October 26, 2009 Category: Pharmaceuticals Source Type: news
Advanced Semantic Knowledge-Based Bio-Medical Search SolutionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
A web browser that can understand technical terms in life sciences and automatically find additional resources and services has been developed by European researchers. It could lead to a new generation of intelligent search engines. The life sciences community has built numerous databases - such as for gene sequencing and information about diseases - that are available to researchers as 'grid' services. (Source: World Pharma News)
Source: World Pharma News - October 26, 2009 Category: Pharmaceuticals Source Type: news
FDA Determines VYVANSE® was Properly Granted Five-Year Market ExclusivityEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate (Source: World Pharma News)
Source: World Pharma News - October 26, 2009 Category: Pharmaceuticals Source Type: news
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Patients with Non-Responsive Thyroid CancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that the companies have begun enrolling patients in an international Phase III trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer. (Source: World Pharma News)
Source: World Pharma News - October 23, 2009 Category: Pharmaceuticals Source Type: news
The 4-T study of intensified insulin regimens shows excellent three-year glucose controlEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
A long-awaited study presented at the International Diabetes Federation World Diabetes Congress in Montreal, Canada, has shown that it is possible for patients with type 2 diabetes to achieve good blood glucose control with a very low rate of major hypoglycaemia[1] even as they intensify their insulin treatment. (Source: World Pharma News)
Source: World Pharma News - October 22, 2009 Category: Pharmaceuticals Source Type: news
Bristol-Myers Squibb Achieves Strong SalesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Bristol-Myers Squibb posted third quarter 2009 net sales from continuing operations of $5.5 billion, an increase of 4%, or 7% excluding foreign exchange impact, compared to the same period in 2008. (Source: World Pharma News)
Source: World Pharma News - October 22, 2009 Category: Pharmaceuticals Source Type: news
Pfizer Reports Third-Quarter 2009 ResultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2009. Revenues were $11.6 billion, a decrease of 3% compared with $12.0 billion in the year-ago quarter. Revenues for third-quarter 2009 compared with the year-ago quarter were unfavorably impacted by approximately $610 million, or 5%, due to foreign exchange and were favorably impacted by $217 million, or 2%, due to a one-time adjustment in the year-ago period for prior years' liabilities for product returns. (Source: World Pharma News)
Source: World Pharma News - October 21, 2009 Category: Pharmaceuticals Source Type: news
Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 PercentEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.49 for the third quarter of 2009, an increase of 21 percent compared to $1.23 for the third quarter of 2008. Adjusted net income increased 16 percent to $1,518 million in the third quarter of 2009 compared to $1,308 million in the third quarter of 2008. (Source: World Pharma News)
Source: World Pharma News - October 21, 2009 Category: Pharmaceuticals Source Type: news
Abbott Completes Visiogen AcquisitionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abbott (NYSE: ABT) has completed its acquisition of privately held eye care company Visiogen, expanding the company's vision care business with a next-generation accommodating intraocular lens (IOL) technology to address presbyopia for cataract patients. (Source: World Pharma News)
Source: World Pharma News - October 20, 2009 Category: Pharmaceuticals Source Type: news
Novartis drug Tasigna® meets primary endpoint in pivotal trial against Glivec®Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
- Tasigna produced faster and deeper responses compared to Glivec as first-line treatment in Philadelphia chromosome-positive chronic myeloid leukemia
- First registration study using molecular response as key indicator of patient outcomes; Bcr-Abl biomarker test measures very low levels of residual disease[1],[2] (Source: World Pharma News)
Source: World Pharma News - October 20, 2009 Category: Pharmaceuticals Source Type: news
FDA approves Micardis® (telmisartan) as the first treatment in its classEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) has approved a new indication for Micardis® (telmisartan) for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors. (Source: World Pharma News)
Source: World Pharma News - October 19, 2009 Category: Pharmaceuticals Source Type: news
FDA approves Cervarix, GlaxoSmithKline's cervical cancer vaccineEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
GlaxoSmithKline (GSK) announced that the U.S. Food and Drug Administration (FDA) has approved CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 for use in girls and young women (aged 10-25). (Source: World Pharma News)
Source: World Pharma News - October 19, 2009 Category: Pharmaceuticals Source Type: news
FDA Approves CRESTOR for Use in Pediatric Patients with Heterozygous Familial HypercholesterolemiaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
AstraZeneca announced the US Food and Drug Administration (FDA) approved CRESTOR (rosuvastatin calcium) for use in children ages 10-17 with heterozygous familial hypercholesterolemia (HeFH) when diet therapy fails to reduce elevated cholesterol. HeFH, a genetic disease, is characterized by high LDL cholesterol (the "bad" cholesterol) and increased risk of early cardiovascular disease. (Source: World Pharma News)
Source: World Pharma News - October 18, 2009 Category: Pharmaceuticals Source Type: news
